Regeneron unveils early, ‘positive’ data for passive vaccination therapy

Jan 26, 2021 - 02:56 PM
COVID19 Web Sized

Regeneron Pharmaceuticals Inc. today announced interim data indicating that its REGEN-COV antibody cocktail could be used as a passive vaccine to prevent COVID-19.

According to Regeneron, the use of an antibody cocktail of casirivimab and imdevimab resulted in 100% prevention of symptomatic infection, and approximately 50% lower overall infection rates. In addition, the lower number of infections during this therapy were asymptomatic, with decreased peak virus levels and short duration of viral shedding.

Infections for those using REGEN-COV lasted no more than one week; in comparison, approximately 40% of placebo group infections lasted three to four weeks.

The interim data, culled from the first 409 evaluable participants enrolled in an ongoing phase 3 trial being run jointly with the National Institutes of Allergy and Infectious Disease, has yet to be peer-reviewed or published in a scientific journal.

Regeneron has an agreement with the Biomedical Advanced Research and Development Authority to supply approximately 1.5 million doses of REGEN-COV to the federal government upon gaining emergency use authorization.

Related News Articles

Headline
FDA seeks feedback on measuring AI-enabled medical device performance
The Food and Drug Administration today issued a request for public comment on a series of questions regarding current approaches to evaluating artificial…
Headline
Olympus recalls endoscope needles
The Food and Drug Administration yesterday announced that Olympus issued a global recall of its ViziShot 2 FLEX needles manufactured prior to May 12 following…
Headline
ACIP recommends patients consult their provider for COVID-19 vaccine
The Advisory Committee on Immunization Practices Sept. 19 recommended that patients should consult their health care provider if they want to receive a COVID-…
Headline
HHS announces efforts to improve long COVID care 
The Department of Health and Human Services Sept. 18 announced it will take new actions to help improve care for individuals with long COVID. They include a…
Headline
FDA issues serious recall for electric wheelchair joysticks
The Food and Drug Administration has identified a Class I recall for Mo-Vis BVBA R-net Joysticks due to a firmware error that causes the wheelchair to ignore…
Headline
CDC releases 2025-26 respiratory disease season outlook
The Centers for Disease Control and Prevention is predicting a similar combined number of peak hospitalizations from COVID-19, the flu and respiratory…